Alkermes plc Presents Data On Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil And ALKS 5461, At 52nd Annual ACNP Meeting

Published: Dec 09, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Alkermes plc (NASDAQ: ALKS) today announced that data will be presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 8-12, 2013, related to the company’s two most advanced clinical candidates, aripiprazole lauroxil, a long-acting injectable treatment for schizophrenia, and ALKS 5461, a novel oral compound for the treatment of major depressive disorder (MDD). Enrollment in the phase 3 study for aripiprazole lauroxil has been completed, and ALKS 5461 is expected to enter phase 3 clinical trials in 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news